Vitamin D Receptor Promotes Healthy Microbial Metabolites
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
United States July 2016 2 Table of Contents
Deuterium Labelled Compounds United States July 2016 2 Table of Contents International Distributors 3 Corporate Overview 4 General Information 5 Pricing and Payment 5 Quotations 5 Custom Synthesis 5 Shipping 5 Quality Control 6 Quotations 6 Custom Synthesis 6 Shipping 6 Quality Control 6 Chemical Abstract Service Numbers 6 Handling Hazardous Compounds 6 Our Products are Not Intended for Use in Humans 7 Limited Warranty 7 Packaging Information 7 Alphabetical Listings 8 Stock Clearance 236 Products by Category 242 n-Alkanes 243 α-Amino Acids, N-Acyl α-Amino Acids, N-t-BOC Protected α-Amino Acid 243 and N-FMOC Protected α-Amino Acids Buffers and Reagents for NMR Studies 245 Detergents 245 Environmental Standards 246 Fatty Acids and Fatty Acid Esters 249 Flavours and Fragrances 250 Gases 253 Medical Research Products 254 Nucleic Acid Bases and Nucleosides 255 Pesticides and Pesticide Metabolites 256 Pharmaceutical Standards 257 Polyaromatic Hydrocarbons (PAHs), Alkyl-PAHs, Amino-PAHs, 260 Hydroxy-PAHs and Nitro-PAHs Polychlorinated Biphenyls (PCBs) 260 Spin Labels 261 Steroids 261 3 International Distributors C Beijng Zhenxiang H EQ Laboratories GmbH Australia K Technology Company Graf-von-Seyssel-Str. 10 Rm. 15A01, Changyin Bld. 86199 Augsburg Austria H No. 88, YongDingLu Rd. Germany Beijing 100039 Tel.: (49) 821 71058246 Belgium J China Fax: (49) 821 71058247 Tel.: (86) 10-58896805 [email protected] China C Fax: (86) 10-58896158 www.eqlabs.de Czech Republic H [email protected] Germany, Austria, China Czech Republic, Greece, Denmark I Hungary, -
Bile Acid Recognition by NAPE-PLD
Articles pubs.acs.org/acschemicalbiology Bile Acid Recognition by NAPE-PLD † ‡ ‡ # † ‡ Eleonora Margheritis, Beatrice Castellani, Paola Magotti, , Sara Peruzzi, Elisa Romeo, § ∥ ∥ ‡ ⊥ † ‡ Francesca Natali, Serena Mostarda, Antimo Gioiello, Daniele Piomelli, , and Gianpiero Garau*, , † Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, 56127 Pisa, Italy ‡ Department of Drug Discovery-Validation, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy § Institute Laue-Langevin (ILL) and CNR-IOM, 71 avenue des Martyrs, 38042 Grenoble, France ∥ Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06125 Perugia, Italy ⊥ Department of Anatomy & Neurobiology, University of California - Irvine, Gillespie NRF 3101, Irvine, California 92697, United States ABSTRACT: The membrane-associated enzyme NAPE-PLD (N- acyl phosphatidylethanolamine specific-phospholipase D) gener- ates the endogenous cannabinoid arachidonylethanolamide and other lipid signaling amides, including oleoylethanolamide and palmitoylethanolamide. These bioactive molecules play important roles in several physiological pathways including stress and pain response, appetite, and lifespan. Recently, we reported the crystal structure of human NAPE-PLD and discovered specific binding sites for the bile acid deoxycholic acid. In this study, we demonstrate that in the presence of this secondary bile acid, the stiffness of the protein measured by elastic neutron scattering increases, and NAPE-PLD is ∼7 times faster to catalyze the hydrolysis of the more unsaturated substrate N-arachidonyl-phosphatidylethanolamine, compared with N-palmitoyl- phosphatidylethanolamine. Chenodeoxycholic acid and glyco- or tauro-dihydroxy conjugates can also bind to NAPE-PLD and drive its activation. The only natural monohydroxy bile acid, lithocholic acid, shows an affinity of ∼20 μM and acts instead as a ≈ μ fi reversible inhibitor (IC50 68 M). -
Campro Catalog Stable Isotope
Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information .............................................................................................. -
• Our Bodies Make All the Cholesterol We Need. • 85 % of Our Blood
• Our bodies make all the cholesterol we need. • 85 % of our blood cholesterol level is endogenous • 15 % = dietary from meat, poultry, fish, seafood and dairy products. • It's possible for some people to eat foods high in cholesterol and still have low blood cholesterol levels. • Likewise, it's possible to eat foods low in cholesterol and have a high blood cholesterol level SYNTHESIS OF CHOLESTEROL • LOCATION • All tissues • Liver • Cortex of adrenal gland • Gonads • Smooth endoplasmic reticulum Cholesterol biosynthesis and degradation • Diet: only found in animal fat • Biosynthesis: primarily synthesized in the liver from acetyl-coA; biosynthesis is inhibited by LDL uptake • Degradation: only occurs in the liver • Cholesterol is only synthesized by animals • Although de novo synthesis of cholesterol occurs in/ by almost all tissues in humans, the capacity is greatest in liver, intestine, adrenal cortex, and reproductive tissues, including ovaries, testes, and placenta. • Most de novo synthesis occurs in the liver, where cholesterol is synthesized from acetyl-CoA in the cytoplasm. • Biosynthesis in the liver accounts for approximately 10%, and in the intestines approximately 15%, of the amount produced each day. • Since cholesterol is not synthesized in plants; vegetables & fruits play a major role in low cholesterol diets. • As previously mentioned, cholesterol biosynthesis is necessary for membrane synthesis, and as a precursor for steroid synthesis including steroid hormone and vitamin D production, and bile acid synthesis, in the liver. • Slightly less than half of the cholesterol in the body derives from biosynthesis de novo. • Most cells derive their cholesterol from LDL or HDL, but some cholesterol may be synthesize: de novo. -
Cholesterol Metabolites 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: from Discovery to Clinical Usage
H OH metabolites OH Review Cholesterol Metabolites 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: From Discovery to Clinical Usage Yaping Wang 1, Xiaobo Li 2 and Shunlin Ren 1,* 1 Department of Internal Medicine, McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, VA 23249, USA; [email protected] 2 Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China; [email protected] * Correspondence: [email protected]; Tel.: +1-(804)-675-5000 (ext. 4973) Abstract: Oxysterols have long been believed to be ligands of nuclear receptors such as liver × recep- tor (LXR), and they play an important role in lipid homeostasis and in the immune system, where they are involved in both transcriptional and posttranscriptional mechanisms. However, they are increas- ingly associated with a wide variety of other, sometimes surprising, cell functions. Oxysterols have also been implicated in several diseases such as metabolic syndrome. Oxysterols can be sulfated, and the sulfated oxysterols act in different directions: they decrease lipid biosynthesis, suppress inflammatory responses, and promote cell survival. Our recent reports have shown that oxysterol and oxysterol sulfates are paired epigenetic regulators, agonists, and antagonists of DNA methyl- transferases, indicating that their function of global regulation is through epigenetic modification. In this review, we explore our latest research of 25-hydroxycholesterol and 25-hydroxycholesterol 3-sulfate in a novel regulatory mechanism and evaluate the current evidence for these roles. Citation: Wang, Y.; Li, X.; Ren, S. Keywords: oxysterol sulfates; oxysterol sulfation; epigenetic regulators; 25-hydroxysterol; Cholesterol Metabolites 25-hydroxycholesterol 3-sulfate; 25-hydroxycholesterol 3,25-disulfate 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: From Discovery to Clinical Usage. -
Genetic Deletion of Abcc6 Disturbs Cholesterol Homeostasis in Mice Bettina Ibold1, Janina Tiemann1, Isabel Faust1, Uta Ceglarek2, Julia Dittrich2, Theo G
www.nature.com/scientificreports OPEN Genetic deletion of Abcc6 disturbs cholesterol homeostasis in mice Bettina Ibold1, Janina Tiemann1, Isabel Faust1, Uta Ceglarek2, Julia Dittrich2, Theo G. M. F. Gorgels3,4, Arthur A. B. Bergen4,5, Olivier Vanakker6, Matthias Van Gils6, Cornelius Knabbe1 & Doris Hendig1* Genetic studies link adenosine triphosphate-binding cassette transporter C6 (ABCC6) mutations to pseudoxanthoma elasticum (PXE). ABCC6 sequence variations are correlated with altered HDL cholesterol levels and an elevated risk of coronary artery diseases. However, the role of ABCC6 in cholesterol homeostasis is not widely known. Here, we report reduced serum cholesterol and phytosterol levels in Abcc6-defcient mice, indicating an impaired sterol absorption. Ratios of cholesterol precursors to cholesterol were increased, confrmed by upregulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase (Hmgcr) expression, suggesting activation of cholesterol biosynthesis in Abcc6−/− mice. We found that cholesterol depletion was accompanied by a substantial decrease in HDL cholesterol mediated by lowered ApoA-I and ApoA-II protein levels and not by inhibited lecithin-cholesterol transferase activity. Additionally, higher proprotein convertase subtilisin/kexin type 9 (Pcsk9) serum levels in Abcc6−/− mice and PXE patients and elevated ApoB level in knockout mice were observed, suggesting a potentially altered very low-density lipoprotein synthesis. Our results underline the role of Abcc6 in cholesterol homeostasis and indicate impaired cholesterol metabolism as an important pathomechanism involved in PXE manifestation. Mutations in the adenosine triphosphate-binding cassette transporter C6 (ABCC6) gene are responsible for pseudoxanthoma elasticum (PXE), a metabolic disease, hallmarked by a progressive elastic fber calcifcation of the skin, eyes and cardiovascular system. -
Hypothalamic Principles Necessary for the Release of Ovulating Hormone from the Adenohypophysis
EFFECT OF AMINOGLUTETHIMIDE ON REPRODUCTIVE PROCESSES IN FEMALE RATS W. J. EVERSOLE and D. J. THOMPSON Department of Life Sciences, Indiana State University, Terre Haute, Indiana 47809, U.S.A. (Received "òlst January 1974) Summary. Adult female rats injected subcutaneously with 100 mg aminoglutethimide phosphate (AGP)/kg/day for 4 weeks failed to become pregnant when placed in cohabitation with males during the last 2 weeks of the injection period. Lower doses depressed the fertility rate and reduced the litter size: the average litter size of three of eleven rats given 50 mg/kg/day was 4\m=.\7 young and of four of eleven rats given 25 mg was 7\m=.\0 young. Twenty-nine controls averaged 10\m=.\1/litter. Doses of 100 mg AGP/kg/day stopped vaginal cycling, prevented ovulation in adults, and delayed dissolution of the vaginal membrane in pubertal rats. Histological studies of the ovaries from rats with initial ages of 17 or 21 days which were injected with 25 to 100 mg AGP/kg/day for 2 weeks showed an increase in the number and size of vesicular follicles. Treatment of 27-day-old rats with 25 mg/kg/day for 2 weeks reduced the number of CL and three of four rats given 50 mg had ovaries lacking such bodies; all control ovaries in this group contained CL. These findings are taken as evidence that AGP inhibits ovulation but does not prevent follicular maturation. INTRODUCTION Many pharmacological compounds originally developed as anaesthetics, tranquillizers and anticonvulsants modify endocrine structures and functions (see Gaunt, Chart & Renzi, 1965). -
Mechanisms of Action of Antiepileptic Drugs
Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal [email protected] ated with less drug–drug interactions. -
Full-Text PDF (Final Published Version)
Alexander, S. P. H., Cidlowski, J. A., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors. British Journal of Pharmacology, 174, S208-S224. https://doi.org/10.1111/bph.13880 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13880 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13880 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Nuclear hormone receptors. British Journal of Pharmacology (2017) 174, S208–S224 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors Stephen PH Alexander1, John A Cidlowski2, Eamonn Kelly3, Neil V Marrion3, John A Peters4, Elena Faccenda5, Simon D Harding5,AdamJPawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical -
Elimination Processes of Guest Molecules from the Inclusion Compounds of Deoxycholic Acid῍
J. Mass Spectrom. Soc. Jpn. Vol. 51, No. 1, 2003 REGULAR PAPER Elimination Processes of Guest Molecules from the Inclusion Compounds of Deoxycholic Acid῍ Takayoshi K>BJG6,῏a) Yuichi K6H6>,a) Tomohide THJ?>BDID,a) Emi K6L6BJG6,a) Tadashi K6B>N6B6,a) and Hatsumi A@>b) (Received November 11, 2002; Accepted December 10, 2002) Thermal behaviors of the inclusion compounds of deoxycholic acid with methanol, ethanol, propane-1-ol, propane-2-ol, and butane-1-ol have been studied by TG-DTA-MS and DSC. Liberation processes of guest molecules from their inclusion compounds of methanol, ethanol were carried out in a single step. Those of propanols and butane-1-ol from the corresponding inclusion compounds proceed in complicated steps. The elimination temperatures, enthalpies and the activation enthalpies of eliminations have been determined by TG, DSC, and MS. 1. Introduction 2. Experimental Bile acids are synthesized from free cholesterol in the Deoxycholic acid (Sigma Chemical Co., Ltd.) was pur- liver and secreted into the small intestine via bile, ified by recrystallization using the purified acetone. All where they aggregate to form micelles in conjunction organic solvents (Kishida Chemical) used as guests with phospholipid or fatty acid. These mixed micelles were fractionally distilled over freshly activated molec- enable the solubilization of lipids and the absorption of ular sieves 4A.6) GLC results of purified solvents fat from the gastrointestinal tract. Also the bile acids showed no trace-impurity peak. Coulometric Karl- form various types of inclusion compounds with many Fischer’s method on a Moisturemeter (Mitsubishi Che- kinds of organic compounds.1) So those inclusion com- mical Ind., CA-02) gave the water content of each pounds might be performed ideal formulation. -
Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors
Neurochemical Research (2019) 44:735–750 https://doi.org/10.1007/s11064-018-02712-1 REVIEW PAPER Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors Sumit Barua1 · Jong Youl Kim1 · Jae Young Kim1 · Jae Hwan Kim4 · Jong Eun Lee1,2,3 Received: 15 October 2018 / Revised: 19 December 2018 / Accepted: 24 December 2018 / Published online: 4 January 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract The central nervous system (CNS) is the most injury-prone part of the mammalian body. Any acute or chronic, central or peripheral neurological disorder is related to abnormal biochemical and electrical signals in the brain cells. As a result, ion channels and receptors that are abundant in the nervous system and control the electrical and biochemical environment of the CNS play a vital role in neurological disease. The N-methyl-D-aspartate receptor, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid receptor, kainate receptor, acetylcholine receptor, serotonin receptor, α2-adrenoreceptor, and acid-sensing ion channels are among the major channels and receptors known to be key components of pathophysiological events in the CNS. The primary amine agmatine, a neuromodulator synthesized in the brain by decarboxylation of L-arginine, can regu- late ion channel cascades and receptors that are related to the major CNS disorders. In our previous studies, we established that agmatine was related to the regulation of cell differentiation, nitric oxide synthesis, and murine brain endothelial cell migration, relief of chronic pain, cerebral edema, and apoptotic cell death in experimental CNS disorders. -
Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders Peter A
University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences 10-19-2010 Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders Peter A. Crooks University of Kentucky, [email protected] Aimee K. Bence David R. Worthen Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Crooks, Peter A.; Bence, Aimee K.; and Worthen, David R., "Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders" (2010). Pharmaceutical Sciences Faculty Patents. 47. https://uknowledge.uky.edu/ps_patents/47 This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US007816407B2 (12) United States Patent (10) Patent N0.: US 7,816,407 B2 Crooks et al. (45) Date of Patent: Oct. 19, 2010 (54) AGMATINE AND AGMATINE ANALOGS IN The Merck Index, Merck Research Laboratories Division of Merck & THE TREATMENT OF EPILEPSY, SEIZURE, Co., Inc. 1996, p. 35. AND ELECTROCONVULSIVE DISORDERS James O. McNamara, “Drugs Effective in Therapy of the Epilepsies”, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, (75) Inventors: Peter A. Crooks, Lexington, KY (US); Ninth Edition, Chapter 20, pp. 461-486, 1996. Aimee K. Bence, Lexington, KY (US); I. Tayfun Uzbay et al., “Effects of agmatine on ethanol Withdrawal David R.